These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1863097)

  • 41. Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia.
    Real JT; Chaves FJ; Martínez-Usó I; García-García AB; Ascaso JF; Carmena R
    Eur Heart J; 2001 Mar; 22(6):465-71. PubMed ID: 11237541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of 3-month treatment of children and adolescents with familial and polygenic hypercholesterolaemia with a soya-substituted diet.
    Weghuber D; Widhalm K
    Br J Nutr; 2008 Feb; 99(2):281-6. PubMed ID: 17697400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A neonatal screening approach to the detection of familial hypercholesterolaemia and family-based coronary prevention.
    Wilcken DE; Blades BL; Dudman NP
    J Inherit Metab Dis; 1988; 11 Suppl 1():87-90. PubMed ID: 3141689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening for familial hypercholesterolaemia.
    Bender R; Bell DA; Hooper AJ; Edwards G; van Bockxmeer FM; Watts GF; Burnett JR
    Pathology; 2012 Feb; 44(2):122-8. PubMed ID: 22228254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experience with plasma-exchange in homozygous familial hypercholesterolaemia.
    Postiglione A; Thompson GR
    Prog Clin Biol Res; 1985; 188():213-20. PubMed ID: 3903770
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of familial hypercholesterolaemia: external validation of the FAMCAT clinical case-finding algorithm to identify patients in primary care.
    Weng S; Kai J; Akyea R; Qureshi N
    Lancet Public Health; 2019 May; 4(5):e256-e264. PubMed ID: 31054643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spectrum of LDLR gene mutations, including a novel mutation causing familial hypercholesterolaemia, in North-western Greece.
    Diakou M; Miltiadous G; Xenophontos SL; Manoli P; Cariolou MA; Elisaf M
    Eur J Intern Med; 2011 Oct; 22(5):e55-9. PubMed ID: 21925044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apolipoprotein B measurement in blood spotted on paper (a screening test for familial type II A hyperlipoproteinemia).
    Koffigan M; Fruchart JC; Dhondt JL; Moschetto Y; Farriaux JP
    Ric Clin Lab; 1982; 12(1):169-72. PubMed ID: 7046018
    [No Abstract]   [Full Text] [Related]  

  • 49. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The concentration of lipid parameters in newborns and in older children].
    Pac-Kożuchowska E
    Med Wieku Rozwoj; 2013; 17(1):53-63. PubMed ID: 23749696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Screening for familial hypercholesterolaemia in relatives.
    Tonstad S; Vollebaek LE; Ose L
    Lancet; 1995 Nov; 346(8987):1438. PubMed ID: 7475864
    [No Abstract]   [Full Text] [Related]  

  • 52. [Serum apolipoprotein and lipoprotein levels in patients with diabetes mellitus type 2].
    Gosiewska A; Zarzycki W; Depta K; Składanek J; Kinalski M; Lopaczyński W
    Wiad Lek; 1989 Apr; 42(7):436-40. PubMed ID: 2629300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE.
    Jarauta E; Pérez-Ruiz MR; Pérez-Calahorra S; Mateo-Gallego R; Cenarro A; Cofán M; Ros E; Civeira F; Tejedor MT
    J Clin Lipidol; 2016; 10(6):1397-1405.e2. PubMed ID: 27919357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands.
    Umans-Eckenhausen MA; Defesche JC; Sijbrands EJ; Scheerder RL; Kastelein JJ
    Lancet; 2001 Jan; 357(9251):165-8. PubMed ID: 11213091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of familial hypercholesterolaemia in premature deaths due to coronary heart disease.
    Leadbeatter S; Williams DW; Stansbie D
    Am J Forensic Med Pathol; 1987 Dec; 8(4):280-2. PubMed ID: 3434546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Familial hypercholesterolaemia and quality of life in family members.
    Hollman G; Olsson AG; Ek AC
    Prev Med; 2003 May; 36(5):569-74. PubMed ID: 12689802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Screening for hypercholesterolaemia on blood spotted filterpaper.
    Asami T
    Lancet; 1983 Jul; 2(8343):229-30. PubMed ID: 6135070
    [No Abstract]   [Full Text] [Related]  

  • 59. Cholesterol screening and family history of vascular disease.
    Primrose ED; Savage JM; Boreham CA; Cran GW; Strain JJ
    Arch Dis Child; 1994 Sep; 71(3):239-42. PubMed ID: 7979498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genotype/phenotype correlations in familial hypercholesterolaemia.
    Nicholls P; Young IS; Graham CA
    Curr Opin Lipidol; 1998 Aug; 9(4):313-7. PubMed ID: 9739486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.